- Bimekizumab improved psoriasis symptoms within 4 weeks.
- More patients achieved DLQI 0/1 with bimekizumab vs secukinumab.
- Higher rates of complete skin clearance (PASI 0) were observed.
- Symptom and quality-of-life benefits were sustained for 3 years.
- Patients switching from secukinumab improved after starting bimekizumab.
Source: JAMA Dermatology
